RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients

Konrad Lewandowski; Katarzyna Karłowicz; Joanna Sarbinowska; Maciej Gonciarz; Dagmara Mahadea; Liliana Łykowska-Szuber; Piotr Eder; Anna Chaber-Ciopińska; Edyta Zagórowicz; Grażyna Rydzewska

doi:10.5114/pg.2026.159896

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Artykuł oryginalny

RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients

Konrad Lewandowski

¹

,

Katarzyna Karłowicz

¹

,

Joanna Sarbinowska

²

,

Maciej Gonciarz

²

,

Dagmara Mahadea

³

,

Liliana Łykowska-Szuber

³

,

Piotr Eder

³

,

Anna Chaber-Ciopińska

^{4, 5}

,

Edyta Zagórowicz

^{4, 5}

,

Grażyna Rydzewska

^{1, 6}

Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
Department of Gastroenterology and Internal Medicine, Military Institute of Medicine – National Research Institute, Warsaw, Poland
Department of Gastroenterology, Dietetics, and Internal Diseases, Poznan University of Medical Sciences, H. Święcicki University Hospital, Poznan, Poland
Department of Oncological Gastroenterology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland
Collegium Medicum, Jan Kochanowski University, Kielce, Poland

Gastroenterology Rev

DOI: https://doi.org/10.5114/pg.2026.159896

Data publikacji online: 2026/03/10

Plik artykułu:

- RESCUE-CD.pdf [0.11 MB]

Pobierz cytowanie

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Lewandowski K, Karłowicz K, Sarbinowska J, et al. RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients. Gastroenterology Review/Przegląd Gastroenterologiczny. 2026. doi:10.5114/pg.2026.159896.

APA

Lewandowski, K., Karłowicz, K., Sarbinowska, J., Gonciarz, M., Mahadea, D.,  & Łykowska-Szuber, L. et al. (2026). RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients. Gastroenterology Review/Przegląd Gastroenterologiczny. https://doi.org/10.5114/pg.2026.159896

Chicago

Lewandowski, Konrad, Katarzyna Karłowicz, Joanna Sarbinowska, Maciej Gonciarz, Dagmara Mahadea, Liliana Łykowska-Szuber,  and Piotr Eder et al. 2026. "RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients". Gastroenterology Review/Przegląd Gastroenterologiczny. doi:10.5114/pg.2026.159896.

Harvard

Lewandowski, K., Karłowicz, K., Sarbinowska, J., Gonciarz, M., Mahadea, D., Łykowska-Szuber, L., Eder, P., Chaber-Ciopińska, A., Zagórowicz, E.,  and Rydzewska, G. (2026). RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients. Gastroenterology Review/Przegląd Gastroenterologiczny. https://doi.org/10.5114/pg.2026.159896

MLA

Lewandowski, Konrad et al. "RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients." Gastroenterology Review/Przegląd Gastroenterologiczny, 2026. doi:10.5114/pg.2026.159896.

Vancouver

Lewandowski K, Karłowicz K, Sarbinowska J, Gonciarz M, Mahadea D, Łykowska-Szuber L et al. RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients. Gastroenterology Review/Przegląd Gastroenterologiczny. 2026. doi:10.5114/pg.2026.159896.

Metryki PlumX:

1. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:

2. 715-25.

3. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3.

4. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL-23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut 2008; 57: 1682-9.

5. Liu M, Zhu W, Wang J, et al. Interleukin-23 receptor genetic polymorphisms and ulcerative colitis susceptibility: a meta-analysis. Clin Res Hepatol Gastroenterol 2015; 39: 516-25.

6. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn’s disease with Th17 cell function: IL-22 serum levels are increased in Crohn’s disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008; 14: 204-12.

7. Wolk K, Witte E, Hoffmann U, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn’s disease. J Immunol 2007; 178: 5973-81.

8. Brand S, Beigel F, Olszak T, et al. IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: G827-38.

9. Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin-23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology 2017; 153: 77-86.e6.

10. D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 2022; 399: 2015-30.

11. Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017; 389: 1699-709.

12. Wang SV, Pottegård A, Crown W, et al. Harmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR task force. Pharmacoepidemiol Drug Saf 2023; 32: 44-55.

Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

RESCUE-CD – Real-world effectiveness of risankizumab in moderate-to-severe Crohn’s disease: a case series involving the most refractory and challenging patients

Konrad Lewandowski 1 , Katarzyna Karłowicz 1 , Joanna Sarbinowska 2 , Maciej Gonciarz 2 , Dagmara Mahadea 3 , Liliana Łykowska-Szuber 3 , Piotr Eder 3 , Anna Chaber-Ciopińska 4, 5 , Edyta Zagórowicz 4, 5 , Grażyna Rydzewska 1, 6

Konrad Lewandowski

¹

,

Katarzyna Karłowicz

¹

,

Joanna Sarbinowska

²

,

Maciej Gonciarz

²

,

Dagmara Mahadea

³

,

Liliana Łykowska-Szuber

³

,

Piotr Eder

³

,

Anna Chaber-Ciopińska

^{4, 5}

,

Edyta Zagórowicz

^{4, 5}

,

Grażyna Rydzewska

^{1, 6}